TBA (last known deadline was October 15, 2012)
Applications are solicited by the Melanoma Research Alliance (MRA) and the Prostate Cancer Foundation (PCF) for one jointly sponsored Team Science Award that will simultaneously advance clinical science in both diseases. A total award amount of up to $1.5 million over 2-3 years is offered to support innovative, meritorious and translational work with the potential for high clinical impact in prostate cancer and melanoma.
The following are examples of investigative areas relevant to both kinds of cancer, for which applications will be considered: 1) nuclear imaging technologies and/or applications as early predictors of treatment outcomes, including novel tracers to distinguish immune from tumor cells in the context of immunotherapy; 2) therapeutic interventions targeting tumor cell metabolism and protein translation; and 3) development of effective combinatorial therapies in the adjuvant or advanced disease setting, based on immune-modulating drugs paired with other agents.
Review of submitted applications will be conducted jointly by PCF and MRA. Proposals must meet all MRA Team Science Award criteria.